Mechanistic Target of Rapamycin Inhibition Prevents Coronary Artery Remodeling in a Murine Model of Kawasaki Disease

Remodeling of the coronary arteries is a common feature in severe cases of Kawasaki disease (KD). This pathology is driven by the dysregulated proliferation of vascular fibroblasts, which can lead to coronary artery aneurysms, stenosis, and myocardial ischemia. We undertook this study to investigate whether inhibiting fibroblast proliferation might be an effective therapeutic strategy to prevent coronary artery remodeling in KD.

[1]  M. Emdin,et al.  Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond , 2022, Cardiac failure review.

[2]  Sarah J. Parker,et al.  Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis , 2021, JCI insight.

[3]  Jae Min Lee,et al.  Seasonal Trends of Viral Prevalence and Incidence of Kawasaki Disease: A Korea Public Health Data Analysis , 2021, Journal of clinical medicine.

[4]  T. Hughes,et al.  The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts. , 2021, Immunity.

[5]  S. Brugaletta,et al.  Durable polymer everolimus-eluting stents: history, current status and future prospects , 2020, Expert review of medical devices.

[6]  M. Jamal-Hanjani,et al.  Transcriptome analysis of IPF fibroblastic foci identifies key pathways involved in fibrogenesis , 2020, Thorax.

[7]  D. Sabatini,et al.  mTOR at the nexus of nutrition, growth, ageing and disease , 2020, Nature Reviews Molecular Cell Biology.

[8]  J. Burns,et al.  Biomarkers of Inflammation and Fibrosis in Kawasaki Disease Patients Years After Initial Presentation With Low Ejection Fraction , 2019, Journal of the American Heart Association.

[9]  I. Wicks,et al.  TNF and IL-1 Play Essential but Temporally Distinct Roles in Driving Cardiac Inflammation in a Murine Model of Kawasaki Disease , 2019, The Journal of Immunology.

[10]  Meic H. Schmidt,et al.  Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. , 2019, Advances in biological regulation.

[11]  G. Smyth,et al.  The Selective Expansion and Targeted Accumulation of Bone Marrow–Derived Macrophages Drive Cardiac Vasculitis , 2019, The Journal of Immunology.

[12]  O. Devinsky,et al.  Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. , 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[13]  P. Cluzel,et al.  mTOR pathway activation in large vessel vasculitis. , 2018, Journal of autoimmunity.

[14]  G. Canaud,et al.  mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G , 2018, Rheumatology.

[15]  R. Nho,et al.  The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis , 2018, International journal of molecular sciences.

[16]  G. Berry,et al.  The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway , 2017, Science Translational Medicine.

[17]  M. Levin,et al.  Dissecting Kawasaki disease: a state-of-the-art review , 2017, European Journal of Pediatrics.

[18]  M. Klingebiel,et al.  Analysis of ribosomal protein S6 baseline phosphorylation and effect of tau pathology in the murine brain and human hippocampus , 2017, Brain Research.

[19]  I. Wicks,et al.  GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease , 2016, The Journal of experimental medicine.

[20]  J. Newburger,et al.  Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population , 2016, Journal of the American Heart Association.

[21]  E. Valjent,et al.  Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to Function , 2015, Front. Mol. Neurosci..

[22]  J. Burns,et al.  Noninvasive Assessment of Peripheral Arteries Adjunctive Testing in the Evaluation of Adults after Kawasaki Disease , 2022 .

[23]  J. Burns,et al.  Cardiovascular pathology in 2 young adults with sudden, unexpected death due to coronary aneurysms from Kawasaki disease in childhood. , 2015, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[24]  M. Portman,et al.  Coronary artery stenosis risk and time course in Kawasaki disease patients: experience at a US tertiary pediatric centre , 2015, Open Heart.

[25]  D. Brenner,et al.  Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. , 2014, The Journal of clinical investigation.

[26]  Sang Gyun Kim,et al.  Rapamycin: one drug, many effects. , 2014, Cell metabolism.

[27]  P. Shao,et al.  Viral infections associated with Kawasaki disease , 2014, Journal of the Formosan Medical Association.

[28]  H. Nojima,et al.  CAWS administration increases the expression of interferon γ and complement factors that lead to severe vasculitis in DBA/2 mice , 2013, BMC Immunology.

[29]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[30]  Kei Takahashi,et al.  Kawasaki disease: basic and pathological findings , 2013, Clinical and Experimental Nephrology.

[31]  J. Orenstein,et al.  Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic Study , 2012, PloS one.

[32]  Lin Sun,et al.  Rapamycin Ameliorates Kidney Fibrosis by Inhibiting the Activation of mTOR Signaling in Interstitial Macrophages and Myofibroblasts , 2012, PloS one.

[33]  K. Obrietan,et al.  Circadian regulation of mammalian target of rapamycin signaling in the mouse suprachiasmatic nucleus , 2011, Neuroscience.

[34]  F. Giles,et al.  The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents , 2009, Targeted Oncology.

[35]  R. Kirsner,et al.  Efficacy of rapamycin in scleroderma: a case study. , 2008, Lymphatic research and biology.

[36]  Y. Adachi,et al.  The influence of culture conditions on vasculitis and anaphylactoid shock induced by fungal pathogen Candida albicans cell wall extract in mice. , 2008, Microbial pathogenesis.

[37]  R. Pearson,et al.  Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function , 2007, Growth factors.

[38]  Kazuo Suzuki,et al.  Lethal and severe coronary arteritis in DBA/2 mice induced by fungal pathogen, CAWS, Candida albicans water-soluble fraction. , 2006, Atherosclerosis.

[39]  N. Wilson,et al.  Kawasaki disease with severe cardiac sequelae: Lessons from recent New Zealand experience , 2004, Journal of paediatrics and child health.

[40]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[41]  T. Kamiya,et al.  Incidence of Stenotic Lesions Predicted by Acute Phase Changes in Coronary Arterial Diameter During Kawasaki Disease , 2004, Pediatric Cardiology.

[42]  C. Hack,et al.  Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. , 2003, Pediatrics.

[43]  C. Weyand,et al.  Medium- and large-vessel vasculitis. , 2003, The New England journal of medicine.

[44]  C. Denton,et al.  Ligand-dependent genetic recombination in fibroblasts : a potentially powerful technique for investigating gene function in fibrosis. , 2002, The American journal of pathology.

[45]  Shankar Srinivas,et al.  Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus , 2001, BMC Developmental Biology.

[46]  T. Kamiya,et al.  Coronary Artery Dilatation Exceeding 4.0 mm During Acute Kawasaki Disease Predicts a High Probability of Subsequent Late Intima-Medial Thickening , 2001, Pediatric Cardiology.

[47]  J. Egan,et al.  Idiopathic pulmonary fibrosis and cyclosporine: a lesson from single-lung transplantation. , 1998, Chest.

[48]  L. W. Perry,et al.  Fatal Kawasaki Disease With Coronary Arteritis and No Coronary Aneurysms , 1998, Pediatrics.

[49]  S. Shulman,et al.  Cardiac transplantation for Kawasaki disease. , 1997, Pediatrics.

[50]  K Hashino,et al.  Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. , 1996, Circulation.

[51]  Kei Takahashi,et al.  Kawasaki Disease With Particular Emphasis on Arterial Lesions , 1991, Acta pathologica japonica.

[52]  T Enright,et al.  Kawasaki syndrome. , 1990, Annals of allergy.